The study utilizes a non-invasive deep brain stimulation (temporal interference, TI) technique primarily targeting the amygdala to preliminarily explore the clinical efficacy and potential mechanisms of MRI-compatible TI technology in regulating the amygdala in depressive disorders, providing a more comprehensive basis for the application of TI technology.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
30
An 8-channel TIS device developed by NEURODOME Corporation.
Shanghai Pudong New Area Mental Health Center
Shanghai, Shanghai Municipality, China
RECRUITINGHAMD-17
Time frame: Baseline, treatment completion day, 1 week, 4 weeks and 8 weeks
HAMA
HAMA is a questionnaire that designed to evaluate the presence and intensity of anxiety symptoms in both clinical and research settings.
Time frame: Baseline, treatment completion day, 1 week, 4 weeks and 8 weeks
SHAPS
The SHAPS is a questionnaire that used to measure the severity of anhedonia, a common symptom in various mental health conditions.
Time frame: Baseline, 4 weeks and 8 weeks
SF-36
Time frame: Baseline and 8 weeks
WHOQOL-BREF
Time frame: Baseline and 8 weeks
PSQI
Time frame: Baseline, 4 weeks and 8 weeks
THINC-it®
THINC-it® is a screening tool for assessment of cognitive functioning in patients with a major depressive episode/disorder
Time frame: Baseline, treatment completion day and 8 weeks
Blood sample
Peripheral blood will be collected at baseline and one 4 weeks after treatment for transcriptomic and proteomic studies to explore the molecular mechanisms of temporal interference (TI) in the treatment of depressive disorders and to identify molecular markers for predicting therapeutic efficacy
Time frame: Baseline, 4 weeks
GAD-7
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: Baseline, treatment completion day, 1 week, 4 weeks and 8 weeks
QIDS-SR
Time frame: Baseline, treatment completion day, 1 week, 4 weeks and 8 weeks
MADRS
Time frame: Baseline, treatment completion day, 1 week, 4 weeks and 8 weeks